LLY Eli Lilly and Company
Company Analysis
Latest News
🟢 LLY is trading 4% up today on strong Q4 earnings and upbeat 2026 guidance
LLY is trading at $1061.76 (+4.01%) in pre-market, rebounding sharply from yesterday's drop following the release of its Q4 2025 financial results. • Revenue...
Eli Lilly Shares Fall Despite Strong Earnings as Hims & Hers Launches Low-Cost Weight-Loss Pill
Eli Lilly shares fell on Thursday. The decline followed the company's Wednesday report of stronger-than-expected earnings. Lilly also issued a robust financial...
🔴 LLY is trading 5.80% down today amid a broad market sell-off and recession fears
LLY is trading at $1042.89 (-5.80%) today, caught in a broader market sell-off driven by recession fears and weak labor data. • The stock's decline follows a...
🔴 LLY is trading 5.2% down today on profit-taking after a massive post-earnings rally
LLY is trading at $1,049.37 (-5.2%) as investors lock in gains following a +10.3% surge driven by blowout Q4 earnings and strong future guidance. • The...
🔴 LLY is trading 4.4% down today amid broader market weakness and tech rotation
LLY is trading at $1058 (-4.44%) in pre-market, pulling back from recent highs as broader market indices face pressure from hawkish Fed concerns and a rotation...
🟢 LLY is trading 9.42% up today after Q4 earnings beat and strong FY2026 guidance
LLY is trading at $1097.95 (+9.42%) following a Q4 2025 earnings beat driven by a 43% surge in revenue to $19.3 billion, fueled by massive demand for Mounjaro...
Eli Lilly's fourth quarter 2025 revenue surged 43% to $19.3 billion, driven by blockbuster sales of Mounjaro and Zepbound.
Eli Lilly reported fourth quarter 2025 revenue of $19.3 billion, a 43% increase year-over-year, driven by strong volume growth. Non-GAAP earnings per share...
Eli Lilly Surges 7% Pre-Market on Tirzepatide Optimism and 31% EPS Growth Forecast
Eli Lilly shares rose 7.18% in pre-market trading on February 4, 2026. The stock reached a price of $1075.49. This follows a close of $1003.46 on February 3....
FDA Extends Review Timeline for Eli Lilly's Oral Obesity Drug Orforglipron
The U.S. Food and Drug Administration (FDA) extended the review period for Eli Lilly's oral GLP-1 weight-loss candidate, orforglipron. The new expected...
Eli Lilly Faces Competitive Headwinds as Oral Obesity Drug Orforglipron FDA Decision is Delayed
Eli Lilly is facing increased competitive pressure in the oral GLP-1 market after the FDA delayed the decision date for its candidate, orforglipron, causing...
Eli Lilly Stock Rises on FDA Obesity Drug Approval Momentum; Valuation Concerns Persist
Eli Lilly shares surged 3.58% to close at $1,078.52, driven by strong investor optimism surrounding the company's leading GLP-1 obesity drug portfolio...
🟢 Eli Lilly is trading 3% up today with market rebound
LLY is trading at $1074 (+3.14%) amid a broader market rebound following yesterday's tariff-driven selloff. Major indices are up modestly (S&P 500 +0.30%,...
Eli Lilly's Oncology Pipeline Receives Major FDA Breakthrough Therapy Designation
Eli Lilly received a significant boost after the U.S. FDA granted Breakthrough Therapy Designation (BTD) to a novel oncology candidate, aiming to fast-track...
Eli Lilly holding steady amid FDA Breakthrough Therapy designation for sofetabart mipitecan and broader market decline
Eli Lilly announced that its investigational drug, sofetabart mipitecan, received FDA Breakthrough Therapy designation for the treatment of platinum-resistant...
Lilly's Ovarian Cancer Drug Candidate Receives FDA Breakthrough Therapy Designation
Eli Lilly and Company announced the FDA granted Breakthrough Therapy designation to its investigational drug, sofetabart mipitecan. The designation targets...
Lilly's Ovarian Cancer Drug Candidate Receives FDA Breakthrough Therapy Designation
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its drug candidate, sofetabart...
Eli Lilly announces FDA Breakthrough Therapy designation for sofetabart mipitecan in pre-market
Eli Lilly announced that the FDA granted Breakthrough Therapy designation to its investigational drug, sofetabart mipitecan (LY4170156), for the treatment of...
Eli Lilly Solidifies Lead in Weight-Loss Drug Market Amid Fierce Competition
Eli Lilly is extending its lead over Novo Nordisk in the rapidly growing weight-loss drug market. Analysts cite the superior effectiveness of Lilly’s Zepbound...
Eli Lilly Shares Plunge Nearly 5% to Hit Four-Week Low Amid Sharp Selling Pressure
Eli Lilly shares suffered a sharp decline on January 15, falling by as much as 4.87% despite overall U.S. markets advancing during the session. The stock...
🔴 Eli Lilly is trading 3% down today after FDA delayed decision on weight-loss pill
Eli Lilly is trading at $1041.07 (-3.00%) after the FDA announced a delay in the decision timeline for its weight-loss pill. * The FDA decision on the drug...